Abstract
Recipharm, a Swedish pharmaceutical services firm, has acquired Arranta Bio, a contract development and manufacturing organization (CDMO) specializing in microbiome therapeutics and messenger RNA production. It also bought Vibalogics, a virotherapy CDMO with expertise in making oncolytic viruses, viral vaccines, and gene therapies. Both firms are based in Massachusetts. Meanwhile, Recipharm plans to expand its sterile fill-and-finish capabilities at its facility in Monts, France, by adding a high-speed filling line.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
